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Background. The microbial etiology of community-acquired pneumonia (CAP) is often unclear in clinical practice, and pre-
vious studies have produced variable results. Population-based studies examining etiology and incidence are lacking. This study 
examined the incidence and etiology of CAP requiring hospitalization in a population-based cohort as well as risk factors and out-
comes for specific etiologies.
Methods. Consecutive admissions due to CAP in Reykjavik, Iceland were studied. Etiologic testing was performed with cul-
tures, urine-antigen detection, and polymerase chain reaction analysis of airway samples. Outcomes were length of stay, intensive 
care unit admission, assisted ventilation, and mortality.
Results. The inclusion rate was 95%. The incidence of CAP requiring hospitalization was 20.6 cases per 10 000 adults/year. 
A potential pathogen was detected in 52% (164 of 310) of admissions and in 74% (43 of 58) with complete sample sets. Streptococcus 
pneumoniae was the most common pathogen (61 of 310, 20%; incidence: 4.1/10 000). Viruses were identified in 15% (47 of 310; 
incidence: 3.1/10 000), Mycoplasma pneumoniae were identified in 12% (36 of 310; incidence: 2.4/10 000), and multiple pathogens 
were identified in 10% (30 of 310; incidence: 2.0/10 000). Recent antimicrobial therapy was associated with increased detection of 
M pneumoniae (P < .001), whereas a lack of recent antimicrobial therapy was associated with increased detection of S pneumoniae 
(P = .02). Symptoms and outcomes were similar irrespective of microbial etiology.
Conclusions. Pneumococci, M pneumoniae, and viruses are the most common pathogens associated with CAP requiring hos-
pital admission, and they all have a similar incidence that increases with age. Symptoms do not correlate with specific agents, and 
outcomes are similar irrespective of pathogens identified.
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Lower respiratory tract infections are a leading infectious 
cause of death worldwide, according the recently published 
2015 Global Burden of Disease Study, with rates increasing in 
many developed countries [1]. Community-acquired pneu-
monia (CAP) refers to infections acquired in the community, 
excluding healthcare-associated disease. Mild cases can be 
treated successfully at home, but severe cases require hospital 
admission and are associated with greater cost and suffer higher 
mortality [2]. Timely and appropriate antibiotic therapy is vital 
to improving outcomes, but minimizing unnecessary use of 
broad-spectrum agents is equally important [2].
Previous studies examining the etiology of CAP have pro-
vided widely differing results. Comparison is hampered by 
inherent epidemiologic differences in addition to lack of uni-
form inclusion criteria, study settings, and diagnostic methods. 
Despite rigorous attempts to identify a microbial etiology, 30%–
64% of patients remain undiagnosed [3–12]. Studies applying 
molecular methods such as polymerase chain reaction (PCR) 
have yielded detection rates up to 86%, but highly specific 
patient selection criteria designed to optimize sample collec-
tion make comparisons difficult [13]. There is a dearth of pop-
ulation-based observational studies with high inclusion rates 
examining pneumonia incidence and etiology while avoiding 
overly selective inclusion criteria and applying modern diag-
nostic methods.
The aim of the present study was to prospectively investigate 
the frequency and etiology of CAP in a defined population, 
allowing for calculation of incidence, applying modern diag-
nostic tests, and comparing etiology with symptoms, risk fac-
tors, and outcomes.
MATERIALS AND METHODS
Patients and Study Design
This study took place at Landspitali University Hospital in 
Reykjavik Iceland (LUH). The LUH provides secondary care 
for the inhabitants of Reykjavik and nearby towns, comprising 
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63% of the national population. It also provides 90% of all 
intensive care in the country. Adults (≥18 years) admitted from 
December 1, 2008 to November 30, 2009 were screened for 
inclusion. Inclusion criteria were a new chest x-ray infiltrate 
and ≥2 additional symptoms: temperature >38.3°C or <36°C, 
diaphoresis, chills, new cough, chest pain, or new onset of dys-
pnea [6, 14]. Exclusion criteria were as follows: admission to an 
acute care facility during the preceding 14 days; use of immuno-
suppressive medications (corticosteroids equivalent to ≥10 mg 
prednisolone daily, methotrexate, hydroxyurea, adalimumab, 
infliximab, etenercept, azathioprine, mycophenolate mofetil, 
or cyclosporine); ongoing treatment for a malignancy; receipt 
of a solid organ transplant; or human immunodeficiency virus 
infection.
Data Collection
Potential participants were approached within 24 hours of ad-
mission and underwent a structured interview, and data were 
collected on underlying diseases, subjective symptoms, and 
antimicrobial use before admission. Pneumonia severity index 
(PSI) and CURB-65 scores were calculated [15, 16]. Outcomes 
were: length of stay (LOS), admission to intensive care units 
(ICUs), assisted ventilation, and in-house mortality. Outcomes 
were obtained retrospectively from patient charts. Vital status 
was cross-checked with national registry data after discharge 
from hospital.
Etiological Testing
The study was noninterventional but included additional diag-
nostic sampling. Sputum and blood were obtained for culture 
prior to in-hospital antimicrobial treatment and urine antigen 
testing was performed. An oropharyngeal swab was collected 
for PCR analysis. Results from physician-ordered etiological 
diagnostic testing were also included.
Sputum and blood were cultured with routine methods 
and susceptibly tested using the Clinical and Laboratory 
Standards Institute methods and criteria [17]. Only results from 
high-quality sputum samples were included [18]. Urine anti-
gens were tested using commercially available tests (BinaxNow 
Streptococcus pneumoniae and BinaxNow Legionella; Inverness 
Medical Innovations).
Oropharyngeal swabs were frozen immediately at −80°C 
for batch analysis with PCR in 2 steps. Samples were initially 
tested for seasonal and pandemic influenza, Mycoplasma pneu-
moniae, Chlamydophila pneumoniae, and Legionella pneumoph-
ila as previously described [19]. Samples were stored at −80°C 
and reanalyzed with multiplex real-time PCR for S pneumo-
niae, Haemophilus influenzae, influenza A  and B, rhinovirus, 
adenovirus, parainfluenza 1–3, respiratory syncytial virus 
(RSV), coronavirus (NL63, OC43, HKU1), enterovirus, metap-
neumovirus, bocavirus, C pneumoniae, and M pneumoniae 
as previously described [20, 21]. Results of real-time PCR for 
S pneumoniae and H influenzae were considered positive at a 
cycle threshold of 35 or less to exclude false-positive results due 
to carriage [21].
Ethics Statement
This study was approved by the LUH ethics committee and 
was in accordance with the revised declaration of Helsinki. 
Informed consent was obtained from all individual participants 
or proxy included in the study.
Statistical Analysis
Statistical calculations were performed using IBM SPSS 
Statistics version 22.0.0.0 (IBM Corporation). Incidence was 
calculated with the average population of 2008 and 2009 derived 
from publically available official data (Statistics Iceland, http://
www.hagstofa.is/Hagtolur/Mannfjoldi). Categorical data 
were compared using χ2 and Fisher’s exact test as appropriate. 
Continuous data were compared with 95% confidence intervals 
(CIs). Risk factors were examined in conjunction with specific 
etiologic results (S pneumoniae, M pneumoniae, and influenza) 
with direct comparison, as detailed above, as well as multi-
nomial logistic regression. Variables that were included in the 
analysis were age, sex, any underlying disease, asthma, chronic 
obstructive pulmonary disease, ischemic heart disease, heart 
failure, diabetes mellitus type 2, underlying neurologic disease, 
chronic renal failure, malignancy, smoking status, recent use of 
antimicrobials, influenza vaccination, pneumococcal vaccin-
ation, fever, cough, purulent cough, hemoptysis, pleuritic chest 
pain, sweating, dyspnea, stomach pain, and diarrhea.
RESULTS
Study Population and Incidence
Of 511 cases approached with suspected pneumonia, 15 (3%) 
chose not to participate and 496 gave consent. Of these, 123 
cases did not meet criteria for pneumonia, and exclusion cri-
teria were present in 63 cases. Thus, 310 admissions were 
included in this study or 95% of all potential cases. The cohort 
is described in Table 1.
The overall incidence of CAP requiring hospital admission 
was 20.6 cases per 10 000 adults per year. Detailed incidence fig-
ures are displayed in Table 2.
Etiology and Yield of Diagnostic Methods
A potential pathogen was identified in 164 (53%) cases. Multiple 
agents were detected in 30 cases (10%; Table 3), and the most 
commonly identified organism was S pneumoniae, (61 cases, 
20%). A respiratory virus was recovered in 47 cases (15%), and 
an atypical bacterial agent (M pneumoniae, C pneumoniae, or 
Legionella species) was recovered in 43 cases (14%). In addition, 
Burkholderia pseudomallei was detected in 1 instance, in a trav-
eler returning from Southeast Asia.
Among cases with multiple pathogens detected (n = 30), the 
most common combination was S pneumoniae with a virus. 
S pneumoniae was detected with influenza in 5 cases (17%), 
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with rhinovirus in 4 cases (13%), and with RSV in 3 cases (10%; 
see Table 3).
Sputum culture was positive in 54 cases (53% of available 
samples); however, only 101 participants (33%) could provide 
an adequate sample. In comparison, blood culture yielded rele-
vant results in 16 (7%) of 231 cases. Polymerase chain reaction 
analysis of 201 available samples resulted in the identification of 
43 (21%) atypical bacterial pathogens and 47 (23%) viruses. In 
addition, 31 (25%) possible cases of S pneumoniae and 12 (12%) 
possible cases of H influenzae were detected using PCR. For S 
pneumoniae, 19 cases were not confirmed by other methods, 
whereas 4 cases of H influenzae were not confirmed by other 
methods. S pneumoniae and H influenzae were identified in 22 
and 30 additional cases, respectively, using multiplex PCR, but 
these were above the cycle threshold and thus excluded from 
further analysis.
A complete set of samples was available in 58 cases (19%) 
(Table 4), an etiological agent was detected in 45 cases (78%), 
and multiple pathogens were identified in 15 cases (26%). S 
pneumoniae and H influenzae were identified at a greater rate 
among patients without recent antibiotic use, whereas M pneu-
moniae was detected more frequently among patients with re-
cent antimicrobial use (Table 4).
Seasonality
The admission rate due to pneumonia was stable during the 
study period. However, viral activity had 2 separate peaks. 
Viral pathogens were detected in 10 of 26 (38%) admissions in 
February and 12 of 29 (41%) in October. The later peak coin-
cided with the 2009 H1N1 influenza pandemic.
Baseline Characteristics and Microbial Agents
Patient characteristics by probable microbial etiology are shown 
in Table 1. Comparison is hampered by the low number of par-
ticipants in some groups. Patients with M pneumoniae and 
influenza were younger and had lower rates of underlying dis-
ease compared with other groups. The mean age of M pneumo-
niae cases was 44.8 years and the mean age of influenza cases 
was 50.1 years, compared with 62.8 years for the entire group 
(Table 1). Despite a low average age, 11 cases of M pneumoniae 
(31%) were over 60 years of age, and the age-specific incidence 
of M pneumoniae admission was highest among the oldest 
patients (6.2/10 000; Table 2). Symptoms were similar regardless 
of detected agent.
We compared the occurrence of the underlying risk factors 
and symptoms displayed in Table 1 with etiology both directly 
and with regression analysis. S pneumoniae was more likely to 
be found in patients without recent antimicrobial use (P = .002, 
Fisher’s exact test) (odds ratio [OR], 3.9; 95% CI, 1.6–9.3; 
P = .002). This association appeared stronger when PCR results 
were excluded (OR, 7.1; 95% CI, 2.1–23.6; P =  .001) and was 
significant on direct comparison (P = .003, Fisher’s exact test). 
Conversely, M pneumoniae was more likely to be identified if 
recent antibiotic use was reported (P < .001, Fisher’s exact test), 
a link that was also found on regression analysis (OR, 11.6; 95% 
CI, 3.2–41.7; P < .001).
The likelihood of identifying influenza was higher amongst 
those not vaccinated against influenza when compared directly 
(P < .001, Fishers exact test) and with regression analysis (OR, 
4.9; 95% CI, 1.1–20.8; P = .03). Hemoptysis was reported in 6 
(21%) influenza cases. All influenza cases with hemoptysis were 
caused by A(H1N1)pdm09 (n = 22), and the association with 
hemoptysis was significant for these cases when compared with 
other participants (P = .02, Fishers exact test).
Severity Scores and Outcomes
The PSI and CURB-65 scores were lowest for patients 
with atypical bacterial infections and influenza (Table  5). 
Mortality was low with 9 deaths (3%). Despite higher rates 
of cultures obtained from these patients, a pathogen was 
detected in only 2 cases (H influenzae and S pneumoniae, 
respectively). Length of stay was similar between groups. 
Patients were admitted to the ICU and received ventilator 
care at similar rates, and no significant differences between 
patients with different pathogens were detected on direct 
comparison (Table  5) or using regression analysis (results 
not shown).
DISCUSSION
A major strength of this study was the high inclusion rate (95%) 
from a well defined population, allowing direct assessment of 
the incidence of CAP requiring hospital admission. The study 
was performed before the introduction of conjugated pneu-
mococcal vaccination in the national childhood immunization 
Table 2. Population Incidence of Community-Acquired Pneumonia Requiring Hospital Admission per 10 000 Adultsa
Type of Pneumonia All Adults Age 18–49 Age 50–64 Age 65–79 Age ≥80
All-cause pneumonia 20.6 8.3 19.1 53.1 127.3
Streptococcus pneumoniae detected 4.1 1.6 3.9 11.1 23.3
S pneumoniae detected (polymerase chain reaction results excluded) 2.8 1.0 2.4 8.0 18.6
Mycoplasma pneumoniae detected 2.4 2.3 2.1 1.9 6.2
Virus detected 3.1 1.5 3.6 7.4 14.0
More than 1 pathogen detected 2.0 1.0 1.5 6.8 7.8
aPopulation statistics derived from publicly available official data (Statistics Iceland: http://www.hagstofa.is/Hagtolur/Mannfjoldi/).
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program, making it an important reference point for further 
studies.
To the authors’ knowledge, only 2 previous studies have ana-
lyzed the incidence of pneumonia requiring hospital admission 
in conjunction with etiological testing utilizing PCR of simi-
lar scope. Takahashi et al [22] found the incidence of CAP in 
Vietnam to be 8 cases per 10 000 adults, but these results are 
difficult to compare with Western studies due to differences 
in healthcare systems in addition to being based on a much 
younger population. In a recent study, Jain et al [12] recruited 
68% of eligible adult patients and estimated the overall inci-
dence of CAP to be 24.8 cases per 10 000 adults per year, which 
is similar to our results. In comparison, Torres et al [23] recently 
determined in a review that the overall incidence of CAP in 
Europe was approximately 16 per 10 000 population.
Several studies have been published over the last decade 
utilizing nucleic acid amplification techniques to assess the 
etiology of pneumonia. A  recent prospective study from the 
United States demonstrated that S pneumoniae accounted for 
5% of pneumonia requiring admission compared with 20% in 
this study. A  possible explanation may be that Jain et  al [12] 
recovered high-quality sputum samples from only 12% of their 
participants compared with 31% in this study. Another contrib-
uting factor may be more widespread vaccination with the con-
jugated pneumococcal vaccine in the US population, which had 
not been introduced in Iceland when this study was performed. 
Another, smaller study set in the United States found S pneumo-
niae in 19% of their cohort, which is similar to our results [10]. 
From Europe, Holter et al [11] recently recovered pneumococci 
in 30% of admitted CAP patients in Norway where conjugated 
pneumococcal vaccine is included in the childhood vaccin-
ation program. Also of note, if results from nasopharyngeal 
culture and upper airway PCR are omitted, the rate was 18% 
[11]. Similarly, Bonten et al [24] found that 21% of CAP cases 
among those >65 years of age were due to S pneumoniae but did 
not use PCR diagnostics. In another recent study, Gadsby et al 
[13] achieved pathogen detection in 87% of patients using PCR 
methods on sputum samples, with S pneumoniae being iden-
tified in 36% of cases. Comparison with our work is difficult, 
however, because Gadsby et al [13] excluded patients unable to 
produce sputum. These recent studies support the results of the 
current study, that 20% of CAP is due to S pneumoniae.
Uniquely, the etiology of pneumonia was examined in the 
population of Reykjavik in 2 simultaneous studies undertaken 
25  years before the current work, which found that S pneu-
moniae caused 39% and 26% of cases [25, 26]. This apparent 
decrease may in part be due to the fact that smoking, a risk fac-
tor for both CAP and invasive pneumococcal disease [27, 28], 
decreased by 50% in the population in the intervening period 
[29]. The decrease in S pneumoniae between these studies 
and the current one is also in line with the decline in rates of 
pneumococcal pneumonia during the last century, as reviewed Ta
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succinctly by Musher et  al [30]. This has not been previously 
illustrated by repeated studies of the same population, to the 
author’s knowledge.
The rate of M pneumoniae was relatively high in this study, 
i.e., identified in 36 cases (12%). In comparison, Jain et  al 
[12] and Gadsby et al [13] identified M pneumoniae in 2% of 
their respective cohorts, whereas Holter et  al [11] found this 
pathogen in 4% of patients. This result may be due to an on-
going local epidemic during the study period, but this ques-
tion requires further study. Younger patients were relatively 
more likely to have M pneumoniae or influenza infections in 
this study. Although M pneumoniae infection is known to be 
common in younger individuals, approximately one third of 
cases were among older patients in this study, and the highest 
incidence was in this group [3]. Mycoplasma pneumoniae is also 
implicated in severe pneumonia; Miyashita et al [31] found that 
6% of patients had severe disease requiring ICU admission. In 
this study, 4 (11%) of patients with M pneumoniae received ICU 
care. In comparison, 5 patients (8%) with S pneumoniae were 
admitted to ICUs.
Although S pneumoniae was identified in 37% of diagnosed 
cases, viruses were also commonly recovered (31%), whereas 
atypical bacteria were found in 28%. Previous studies have 
found viral pathogens in 15%–32% of patients with CAP [6–8, 
12, 13, 32]. Influenza was the most common virus, and most 
cases were infected with the H1N1 pandemic strain and admit-
ted during October 2009. It has previously been shown that the 
elderly population was relatively protected from the pandemic 
influenza A(H1N1)pdm09 strain, likely due to cross-reactive 
immune responses [33].
We found that 107 (35%) patients reported receiving antibiot-
ics before admission, similar to previous reports (11%–32%) [6, 
Table 4. Pathogens Detected in Cases of Community-Acquired Pneumonia and Results From Cases With Complete Sample Sets Available for Etiologic 
Testinga
Complete Sample Sets Available
Entire Cohort No Antimicrobial Before Admissionb Antimicrobial Before Admissionb All Cases
n 310 37 21 58
No pathogen detected 146 (47) 8 (22) 5 (24) 13 (22)
Single pathogen detected 134 (43) 16 (43) 14 (67) 30 (52)
More than 1 pathogen 
detected
30 (10) 13 (35) 2 (10) 15 (26)
Pathogens detected
Mycoplasma pneumoniae 36 (12) 2 (5)c 10 (48)c 12 (21)
Streptococcus pneumoniae 61 (20) 12 (32) 3 (14) 18 (31)
Haemophilus influenzae 22 (7) 8 (22) 2 (10) 10 (17)
Influenza A 27 (9) 6 (16) 1 (5) 7 (12)
Moraxella catarrhalis 7 (2) 5 (14) 0 (0) 5 (9)
Rhinovirus 6 (2) 3 (8) 0 (0) 3 (5)
Chlamydophila pneumoniae 4 (1) 1 (3) 1 (5) 2 (3)
Metapneumovirus 3 (1) 2 (5) 0 (0) 2 (3)
RSV 6 (2) 1 (3) 1 (5) 2 (3)
Staphylococcus aureus 8 (3) 1 (3) 1 (5) 2 (3)
Burkholderia pseudomallei 1 (0.3) 1 (3) 0 (0) 1 (2)
Influenza B 1 (0.3) 1 (3) 0 (0) 1 (2)
Legionella species 3 (1) - - -
Pseudomonas aeruginosa 2 (0.6) - - -
Klebsiella pneumoniae 1 (0.3) - - -
Mycobacterium avium 1 (0.3) - - -
Coronavirus 2 (0.6) - - -
Bocavirus 1 (0.3) - - -
Parainfluenza 1 (0.3) - - -
Oropharyngeal PCR results excluded
S pneumoniae 42 (14) 10 (27)d 1 (5)d 11 (19)
H influenzae 18 (6) 8 (22) 2 (10) 10 (17)
Abbreviations: PCR, polymerase chain reaction; RSV, respiratory syncytial virus.
NOTE: Data presented as n (%). 
aTests performed were cultures of sputum and blood, antigen testing of urine, and PCR analysis of upper airway swabs.
bPatient reported data.
cThe different detection rates of M pneumoniae among those with and without prior antimicrobial was statistically significant (P < .001; Fisher’s exact test).
dThe different detection rates of S pneumoniae among those with and without prior antimicrobial use was statistically significant when PCR results were excluded (P < .05; Fisher’s exact 
test).
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7, 12, 34]. Prior antibiotic use was associated with detection of 
M pneumoniae, a correlation that has been noted previously 
[35]. It is possible that this reflects the lack of therapeutic re-
sponse to empiric antimicrobial therapy against pneumonia in 
the outpatient setting, which commonly consists of β-lactams, 
but would be worthy of further study. Conversely, the odds of 
identifying S pneumoniae were increased in patients without re-
cent antimicrobial use. It is also possible that participants who 
had received prior treatment had more drawn out symptoms 
indicative of different etiology. Some previous studies have 
excluded patients unable to produce sputum or with recent anti-
microbial use to improve diagnostic yield [6, 13]. Our results, 
which include the vast majority of eligible patients, indicate 
that such an approach may introduce a major selection bias by 
excluding infections caused by “atypical” bacteria and viruses 
and preferentially include pneumonia caused by S pneumoniae.
Despite our diagnostic attempts, we did not find any etiology 
for 47% of patients in this study. This is common and 2 recent 
studies found no etiology in 37%–62% of patients [11, 12]. The 
reasons for this are unclear, and this is an important area for 
further study.
This study indicated that the likelihood of detecting pan-
demic influenza A(H1N1)pdm09 was increased for patients 
reporting hemoptysis. This strain has been associated with 
more severe disease than seasonal influenza [19]. Blood in 
sputum was reported in 30% of the first influenza A(H1N1)
pdm09 cases from Mexico in 2009, whereas hemorrhagic tra-
cheitis and bronchitis has been noted as a histological feature 
in severe cases in prior influenza pandemics [36, 37]. Other 
reported symptoms were similar in all groups and did not help 
in discerning between different etiologies. The lack of correl-
ation of symptoms with etiology has been demonstrated previ-
ously and is confirmed by these results [38].
Mortality was relatively low (3%) compared with many pre-
vious studies (2%–15%), possibly due to differences in setting 
and inclusion criteria [3, 4, 7, 12, 39]. Jain et  al [12] found 
a similar mortality (2%) in their cohort and a similar PSI 
score despite being younger, whereas 21% of their patients 
were admitted to ICU and 6% required invasive ventilation. 
Corresponding results from this study are 5% and 2%, respect-
ively, if cases due to the H1N1 pandemic are excluded (Table 5). 
Conversely, the median LOS was 3 days in the study by Jain et al 
[12] compared with 7 in the current study, probably reflecting 
major differences in management approaches to this problem 
between a Nordic country and the United States. Holter et  al 
[11] examined a Norwegian cohort with an identical median 
age to ours and found a similar LOS (7 days), and although 18% 
were admitted to ICU, the mortality was 4%. It is likely that 
systemic factors and different thresholds for ICU admission, 
timing of switching from intravenous to oral, and transfer to 
outpatient management may explain some of these differences 
[11, 12].Ta
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Rates of ICU admissions, use of assisted ventilation, and 
LOS were similar for patients irrespective of organisms 
identified. It is notable that patients with atypical pathogens 
had lower PSI and CURB-65 scores than other patients but 
required similar ICU care and LOS. Because both scores 
include age as risk factors, the relatively low age of influenza 
and M pneumoniae patients may offer a partial explanation. 
Severity scores and outcomes were also similar for patients 
with an identified virus when compared with other patients. 
Although pandemic influenza cases heavily influenced this 
result, they did not account for all morbidity in this group. 
Patients with dual pathogens had a trend towards worse out-
comes, but the number of patients was low and therefore a 
great potential for type II error.
This study has several limitations. As in similar studies, no 
potential etiology was identified for a sizeable group of partic-
ipants. Despite the high level of patient inclusion, we were not 
able to collect all tests for all participants: a more complete sam-
ple set might have resulted in the detection of more potential 
pathogens. We chose to collect oropharyngeal swabs for PCR 
analysis to optimize sample collection and patient recruitment. 
It is possible that use of nasopharyngeal samples may have 
increased sensitivity for respiratory viruses [40]. In addition, 
an organism identified from the upper airway cannot always 
be assumed to be the causative agent for pneumonia, and PCR 
results for some organisms must be interpreted as suggestive for 
possible etiology. It is also possible that our method of batch 
analysis and storage may have decreased the sensitivity of our 
laboratory methods. When comparing the statistical results of 
this study, the number of relevant variables in comparison with 
the cohort size, particularly for individual etiologies, must be 
kept in mind as in other comparable studies. We applied mul-
tinomial regression as part of our analysis, but there is a risk of 
overfitting due to small numbers of individual outcomes, cohort 
size, and number of variables. The results of direct comparisons 
are reported alongside these results but must also be interpreted 
with the number of comparisons in mind. Both of these factors 
increase the risk of type I error.
CONCLUSIONS
This population-based study with a 95% inclusion rate demon-
strates an incidence of CAP requiring hospitalization of 20.6 
cases per 10 000 adults/year. S pneumoniae was the most fre-
quently identified pathogen. The incidence of M pneumoniae 
was highest amongst the oldest patients, similar to the other 
pathogens examined. Study designs that exclude participants 
with prior antibiotic use or unable to produce sputum to 
increase diagnostic yield may lead to biased results and miss 
certain pathogens. Clinical signs and symptoms were of limited 
use for identifying patients with a respiratory virus or atypical 
bacterial infection, and, despite lower severity scores among 
these patients, LOS and rates of ICU admission and need for 
assisted ventilation were similar regardless of microbial etiology.
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